XENE Share Price Performance
US$58.80
21.58 (57.98%)
27.0% undervalued intrinsic discount
US$80.56
Fair Value
Price US$58.80
AnalystConsensusTarget US$80.56
AnalystHighTarget US$100.00
AnalystLowTarget US$69.00
Fair ValueUS$80.56
Share Pricen/a
Xenon Pharmaceuticals Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
XENE Community Narratives
AN
Fair Value
·Fair Value US$80.56 27.0% undervalued intrinsic discount
Epilepsy And Mood Disorder Therapies Will Drive Long-Term CNS Leadership
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$100 41.2% undervalued intrinsic discount
Late Stage Neuroscience Pipeline Will Transform Ion Channel Franchise Over The Coming Years
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$69 14.8% undervalued intrinsic discount
Epilepsy And Depression Pipeline Will Define Fair Long Term Outlook
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Xenon Pharmaceuticals
14.8% undervalued intrinsic discount
Epilepsy And Depression Pipeline Will Define Fair Long Term Outlook
View narrativeAN
Updated 9 Aug
Xenon Pharmaceuticals
27.0% undervalued intrinsic discount
Epilepsy And Mood Disorder Therapies Will Drive Long-Term CNS Leadership
View narrativeAN
Updated 10 Jul
Xenon Pharmaceuticals
41.2% undervalued intrinsic discount
Late Stage Neuroscience Pipeline Will Transform Ion Channel Franchise Over The Coming Years
View narrativeAN
Published 9 Mar
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
XENE: Upcoming NDA Filing And Kv7 Data Readouts Will Shape Risk Balance
Fair Value: US$69 14.8% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
XENE: Epilepsy Trial Progress Will Define Edge Versus Slower Kv7 Rival
Fair Value: US$80.56 27.0% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Late Stage Neuroscience Pipeline Will Transform Ion Channel Franchise Over The Coming Years
Fair Value: US$100 41.2% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Xenon Pharmaceuticals Inc. Key Details
About XENE
- Founded
- 1996
- Employees
- 364
- CEO
- WebsiteView website
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company’s Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
